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Abstract
Background: Calstabins 1 and 2 bind to Ryanodine receptors regulating muscle excitation-contraction coupling.
Mutations in Ryanodine receptors affecting their interaction with calstabins lead to different cardiac pathologies.
Animal studies suggest the involvement of calstabins with dilated cardiomyopathy.
Results: We tested the hypothesis that calstabins mutations may cause dilated cardiomyopathy in humans
screening 186 patients with idiopathic dilated cardiomyopathy for genetic alterations in calstabins 1 and 2 genes
(FKBP12 and FKBP12.6). No missense variant was found. Five no-coding variations were found but not related to the
disease.
Conclusions: These data corroborate other studies suggesting that mutations in FKBP12 and FKBP12.6 genes are
not commonly related to cardiac diseases.
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Background
Ryanodine receptors (RyRs) are the main proteins in the
sarcoplasmic reticulum (SR) calcium-release channel and
are modulated by other proteins in the regulation of mus-
cle excitation-contraction coupling[1]. Calstabins 1 and 2
(FKBP12 and FKBP12.6 genes, respectively) bind both
RyR1 (skeletal form) and RyR2 (cardiac form) although
calstabin1 has higher affinity to RyR1, and calstabin2 to
RyR2 [2-4]. The RyR-calstabin interaction occurs to stabi-
lize the RyR channel in the closed state, but its specific
amino acids binding site is still controversial [5-7].
Although, calstabin1 deficient mice display normal skeletal
muscle phenotype, they have severe Dilated Cardiomyopa-
thy (DCM) and ventricular septal defects [8]. Mice with a
disruption in calstabin2 display hypertrophic cardiomyo-
pathy only in males. However, both males and females
present a similar dysregulation of Ca2+ release [9].
Disease-causing mutations in RyRs 1 and 2 affecting
the interaction with calstabins were described as leading
to different phenotypes [1]. Wehrens and colleagues
reported RyR2 mutations which decrease the affinity of
RyR2 with calstabin2 in patients with Catecholaminergic
Polymorphic Ventricular Tachycardia (CPVT) [7]. How-
ever, no mutation in calstabin2 seemed to be involved
with the disease [10]. The association of calstabins with
heart disease was also tested in a familial Hypertrophic
Cardiomyopathy cohort, and no mutation was found in
all 252 patients [11]. Recently, Oyama and colleagues
have reported an increased expression of FKBP12.6 gene
in Great Dane dogs with DCM [12]. These results, taken
together with the dilated cardiomyopathy phenotype of
calstabin1 knockout mice, suggest that calstabins may be
associated with DCM development. Thus, the aim of the
present study is to test the hypothesis that mutations in
calstabins genes (FKBP12 and FKBP12.6) occur, and can
cause human DCM phenotype.
Results
Considering the 186 Idiopathic Dilated Cardiomyopathy
(IDC) patients screened, 75% were male and 25% female.
The mean age was 44.8 ± 12.4. The population had the* Correspondence: alexandre.pereira@incor.usp.br1Laboratory of Genetic and Molecular Cardiology, Heart Institute, University
of Sao Paulo Medical School, Brazil
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following ethnic distribution: 14.5% blacks, 15.5% mullatos
and 69.8% whites.
No missense mutation was found in FKBP12 nor in
FKBP12.6. Five new allelic variants were found (Table 1).
Two of them were found in the control group (age and
ethnic matched) with no significant difference in allelic
nor genotypic frequency. Three allelic variants, one in
the promoter region and two in the Exon1 5’UTR of
FKBP12, were not present in the control group. Bioinfor-
matics data suggest that these allelic variants have a very
low or none probability to be pathological. From all SNPs
found in our population, only one SNP with minor allelic
frequency (MAF) not available in dbSNP was found
(Table 2). All the alterations in cases and controls met
the Hardy-Weinberg equilibrium.
Discussion
Data from animal models point out FKBPs as important
candidate genes for cardiac diseases. In fact, several muta-
tions in RyR1 and RyR2 proteins cause decreased affinity
between RyRs and calstabins, leading to abnormal calcium
cycling, a major hallmark of several cardiac phenotypes,
including heart failure. Mutations affecting RyR-calstabin
interactions are well described for some diseases such as:
Left Ventricule Noncompaction (LVNC), Central Core
Disease (CCD) and Catecholaminergic Polymorphic Ven-
tricular Tachycardia (CPVT). However, little is known if
mutations in calstabins could lead to disease by them-
selves. Genetic analyses of FKBP12 were done only in two
cohorts of diseases (LVNC (48 patients) [13] and CCD (27
patients) [14]) and in one family with LVNC. No mutation
was found in any of this studies. Recently, genetic analyses
of FKBP12.6 have been done in 16 patients with CPVT
and in 232 patients with hypertrophic cardiomyopathy
and, also, no mutations were found.
To our knowledge, this study has been the first report of
calstabins 1 and 2 genetic screening in idiopathic DCM
patients. We found five new allelic variations and none of
them caused amino acid change. The alterations c.*26G>A
in FKBP12.6 gene and -40C>A in FKBP12 gene were also
found in the control population. For the three other altera-
tions we measured the risk of being disease-causing by the
analyses of three different bioinformatics software, con-
cerning their possible involvement in splicing, microRNA
and transcription factor binding sites [15-17]. The -7G>A
alteration in the promoter region of FKBP12 was predicted
as low risk, although its create a new biding site for the
NRF2 transcription factor (TF). NRF2 enhances gene
expression in response to oxidative stress, which is
involved in the development and progression of heart fail-
ure [18,19]. This suggests that the -7G>A alteration could
result in overexpression of FKBP12 gene. Although over-
expression of FKBP12 gene has been described modulating
RyR2 in rabbit myocytes [20], we believe that this muta-
tion alone could not be responsible for disease develop-
ment, once the concentration of calstabin1 in the heart is
naturally much higher than calstabin2 and does not hinder
calstabin2 interaction with RyR2 [4]. Further studies are
needed to assess the impact of the overexpression of cal-
stabins1 in human cardiomyocytes. The c.-72C>G and c.-
65C>G alterations in the exon 1 5’UTR region were pre-
dicted with none risk to be related with the disease. Over-
all, we did not find any alterations possibly related with
the disease.
We found 7 silent SNPs with MAFs ranging between
MAFs of European and African populations, which are the
main founders of Brazilian population. Among the SNPs
presented in the sequenced regions with allelic frequency
described on dbSNP, only one was not found in our popu-
lation (data not shown- rs77743612). This may be
explained by its low MAF in the Yoruba population (0.014)
and absence in the CEU population. Since these silent
SNPs were not overrepresented in our population, it is
quite improbable that they might be related with the
disease.
Today, mutations in about 35 genes are described in
idiopathic DCM. Together, they do not explain more than
10% of cases, indicating that more genes might be involved
with the disease pathogenesis. Animal models suggested
that calstabin proteins might be associated with DCM.
Our result, taken together with other calstabin genetic
screening efforts, leads us to believe that mutations in
FKBP12 and FKBP12.6 genes are not commonly related to
cardiac diseases.
Conclusion
Calstabin 1 and 2 are not involved in idiopathic DCM
development in Brazilian patients.
Table 1 New allelic variants found in FKBP12 and FKBP12.6 gene.
Gene Site MAF: cases
(n = 186)
Reference
(coding DNA)
MAF: controls
(n = 288)
p value Risk by bioinformatics analyses
FKBP12 Promoter 0.0026 -40C>A 0.0052 0.25 -
FKBP12 Promoter 0.0026 -7G>A 0 - Low
FKBP12 Exon 1 - 5’ UTR 0.0026 c.-72C>G 0 - None
FKBP12 Exon 1 - 5’ UTR 0.0026 c.-65C>G 0 - None
FKBP12.6 Exon 4 - 3’UTR 0.0026 c.*26G>A 0.0017 0.55 -
MAF: Minor Allele Frequency
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Methods
Study population
One-hundred-eighty-six (186) patients with Idiopathic
Dilated Cardiomyopathy (IDC) were selected from two
different heart failure cohorts from the Heart Institute
(InCor), University of São Paulo Medical School. In both
groups, the diagnosis of heart failure was made according
to previously published criteria [21,22]. The heart failure
etiology classification followed previous recommenda-
tions[22]. As such, the diagnosis of chronic heart failure
was made through both clinical and imaging procedures
when necessary. Ischemic cardiomyopathy diagnosis was
made when a clear history of previous myocardial infarc-
tion and no other probable causes of heart dysfunction
were present or, alternatively, through coronary angio-
graphy. All patients with the final diagnosis of idiopathic
dilated cardiomyopathy were studied through coronary
angiography to exclude the diagnosis of ischemic cardio-
myopathy. Table 3 shows clinical and functional charac-
teristics of the IDC Cohort.
Molecular Genetic Analyses
Extraction of genomic DNA was performed from leuko-
cytes separated from whole blood using a standard salting-
out method [23]. DNA samples were further diluted with
PCR grade water to a concentration of 10 ng/μL. All cod-
ing exons and flanking sequences of FKBP12 (reference
sequence: NM_000801.3) and FKBP12.6 (reference
sequence: NM_004116.3) were analyzed for mutations,
with at least 20 nucleotides into introns. Intronic primers
were designed using the software Primer3 [24]. The final
optimal reaction conditions were empirically determined;
primer sequences are described in Table 4, and PCR con-
ditions are available upon request. Samples were pre-
selected for bidirectional sequencing by High-Resolution
Melting (HRM) curves manually analyzed or were bidirec-
tionally sequenced directly. For HRM, the reaction mix-
ture used BioTaq DNA Polymerase (BioQuimica, Brazil)
and consisted of 10 ng of genomic DNA, 1× Assay buffer,
2 mM MgCl2, 200 nM of each primer, 200 μM of dNTPs,
1,5 μM of SYTO9 (Invitrogen, Carlsbad, USA), 0.5 U of
BioTaq DNA Polymerase and PCR grade water in a
volume of 10 μL. PCR cycling and HRM analysis were per-
formed on the Rotor-Gene™ 6000 equipment (Qiagen,
Courtaboeuf, France). Bidirectional sequencing was per-
formed by 3500xL Genetic Analyzer (Applied Biosystems,
EUA) using BigDye® Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems, EUA) and manufacturer proto-
cols. The frequency of all identified variants was deter-
mined in 288 age and ethnic matched controls by HRM.
The importance of variants out of coding regions that
were not present in the control sample was analyzed
in silico by FastSNP[17], MutationTaster [15] and
Table 2 SNPs found in FKBP12 and FKBP12.6 gene in cases.
Gene Site SNP Troca MAF: cases
(n = 186)
MAF: dbSNP
(YRI - CEU)
FKBP12 Intron 2 rs6074549 C/G 0.0026 0.008 - 0
FKBP12.6 Exon 1 - 5’ UTR rs116520786 C/T 0.14 0.25 - 0
Exon 1 - 5’ UTR rs111634163 C/T 0.06 NA
Intron 3 rs13016301 A/T 0.07 0 - 0.18
Intron 3 rs1424344 C/T 0.18 0.32 - 0
Exon 4 - 3’UTR rs14388 C/T 0.17 0.4 - 0.008
Exon 4 - 3’UTR rs114658911 C/T 0.005 0 - 0.005
MAF: Minor Allele Frequency; NA: Not Available; CEU: Northern and Western Europe; YRI: Yoruba in Ibadan, Nigeria
Table 3 Clinical and functional characteristics of IDC
Cohort
IDC Cohort
Clinical
Biochemical
Hemoglobin (mg/dL) 12.7 ± 1.97
Total Cholesterol (mg/dL) 185 ± 55
Triglycerides (mg/dL) 106 ± 56
HDL (mg/dL) 45.7 ± 17.3
LDL (mg/dL) 116 ± 44
Creatinin (mg/dL) 1.2 ± 0.3
BMI (kg/m2) 25.08 ± 4.65
Heart Rate (pm) 76.35 ± 13.57
Diastolic Blood Pressure (mmHg) 67.41 ± 14.56
Systolic Blood Pressure (mmHg) 104.44 ± 18.9
Echocardiographic
Left Atrium Diameter, mm 47.52 ± 8.48
Aortic Diameter, mm 32.57 ± 4.26
Right Ventricle Diameter, mm 27.19 ± 6.14
Left Ventricle
Intraventricular Septum, mm 8.39 ± 1.48
Posterior Wall Thickness, mm 8.31 ± 1.21
Diastolic Diameter, mm 73.55 ± 10.06
Systolic Diameter, mm 64.01 ± 9.58
Ejection Fraction, (%) 35.08 ± 8.9
Mass, g 268.74 ± 77
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miTarget [16]; concerning the transcription factor bind-
ing site, splicing and miRNA binding sites, respectively.
Statistical analysis
Data are presented as mean ± standard deviation (SD)
for continuous variables and as frequencies for categori-
cal variables. Statistical analyses were performed with
SPSS software 13.0. Hardy-Weinberg equilibrium was
evaluated by a Chi-square test. Allelic frequencies com-
parison was evaluated Fisher’s exact test.
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